AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

MRK · NYSE · Drug Manufacturers - General

Merck (MRK)

Develops oncology medicines, vaccines, cardiopulmonary therapies, and animal-health products worldwide.

$150.72

After hours−0.19 (−0.13%)

At close$150.92(+0.95%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	15,962	14,630	15,775	16,112	16,657	15,624	15,619	15,800	17,183	16,324	16,286	16,607
Cost of revenue	4,264	3,912	3,540	3,745	4,080	3,828	3,885	3,847	4,194	4,817	2,944	4,395
Gross profit	11,698	10,718	12,235	12,367	12,577	11,796	11,734	11,953	12,989	11,507	13,342	12,212
	5,826	12,431	6,475	6,239	8,593	7,448	5,024	5,594	5,526	5,347	15,226	12,895
Research & development	3,307	9,627	3,992	3,500	5,862	4,584	3,119	3,540	3,552	2,499	12,558	9,741
	2,519	2,641	2,483	2,739	2,731	2,691	1,905	2,054	1,974	2,848	2,668	2,904
Selling & marketing	0	2,300	0	0	0	2,400	0	0	0	0	0	0
General & administrative	0	341	0	0	0	291	0	0	0	0	0	2,904
Other expenses	0	163	0	0	0	173	0	0	0	0	0	250
Operating income	5,872	−1,713	5,760	6,128	3,984	4,348	6,710	6,359	7,463	6,160	−1,884	−683
	−252	−333	−90	−122	106	−178	−807	−1,360	−718	−2,740	−1,650	0
Interest income	73	70	73	69	127	146	109	69	96	69	0	35
Interest expense	317	310	303	310	330	328	313	305	327	411	0	525
Other non-operating income	−65	23	−213	−188	−436	−150	494	1,055	391	2,329	1,650	−525
Income before tax	5,620	−2,046	5,670	6,006	4,090	4,170	5,903	4,999	6,745	3,420	−3,534	−683
Income tax expense	870	−820	903	545	929	426	818	571	958	458	709	654
Net income from continuing operations	4,750	−1,226	4,767	5,461	3,161	3,744	5,085	4,428	5,787	2,962	−4,243	−1,337
Net income	4,745	−1,226	4,762	5,455	3,157	3,743	5,079	4,427	5,785	2,963	−4,240	−1,335
EPS, basic	$1.87	−$0.48	$1.88	$2.15	$1.25	$1.48	$2.01	$1.76	$2.32	$1.20	−$1.72	−$0.54
EPS, diluted	$1.86	−$0.48	$1.87	$2.14	$1.24	$1.48	$2.01	$1.76	$2.32	$1.19	−$1.72	−$0.54
Weighted average shares, basic	2,537	2,554	2,533	2,534	2,541	2,541	2,523	2,510	2,495	2,475	2,472	2,472
Weighted average shares, diluted	2,546	2,554	2,544	2,544	2,541	2,541	2,531	2,513	2,498	2,488	2,472	2,472
EBITDA	6,951	−772	6,957	7,448	5,606	5,695	7,315	6,360	8,144	6,297	−2,022	1,425
Depreciation & amortization	1,014	964	984	1,132	1,186	1,197	1,099	1,056	1,072	2,466	1,512	1,583
EBIT	5,937	−1,736	5,973	6,316	4,420	4,498	6,216	5,304	7,072	3,831	−3,534	−158